Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Elizabeth George
Institution:
Nationwide Children's Hospital
Observed institution:
Nationwide Children's Hospital
ORCID:
0009-0009-4627-2822
Observed ORCID:
0009-0009-4627-2822
OpenAlex ID:
A5140688130
Safety and Clinical Outcomes of a First-in-Human Trial of Point-of-Care Manufactured Trispecific CAR T Cells Targeting CD19, CD20, and CD22
2026
·
Sumithira Vasu
, Nathan Denlinger
, et al.
·
Blood Cancer Discovery
·
1
PDF
Supplementary Figure 5 from Safety and Clinical Outcomes of a First-in-Human Trial of Point-of-Care Manufactured Trispecific CAR T Cells Targeting CD19, CD20, and CD22
2026
·
Sumithira Vasu
, Nathan Denlinger
, et al.
Supplementary Table 3 from Safety and Clinical Outcomes of a First-in-Human Trial of Point-of-Care Manufactured Trispecific CAR T Cells Targeting CD19, CD20, and CD22
2026
·
Sumithira Vasu
, Nathan Denlinger
, et al.
Supplementary Table 1 from Safety and Clinical Outcomes of a First-in-Human Trial of Point-of-Care Manufactured Trispecific CAR T Cells Targeting CD19, CD20, and CD22
2026
·
Sumithira Vasu
, Nathan Denlinger
, et al.
Clinical Protocol 1 from Safety and Clinical Outcomes of a First-in-Human Trial of Point-of-Care Manufactured Trispecific CAR T Cells Targeting CD19, CD20, and CD22
2026
·
Sumithira Vasu
, Nathan Denlinger
, et al.
Data from Safety and Clinical Outcomes of a First-in-Human Trial of Point-of-Care Manufactured Trispecific CAR T Cells Targeting CD19, CD20, and CD22
2026
·
Sumithira Vasu
, Nathan Denlinger
, et al.
Supplementary Figure 1 from Safety and Clinical Outcomes of a First-in-Human Trial of Point-of-Care Manufactured Trispecific CAR T Cells Targeting CD19, CD20, and CD22
2026
·
Sumithira Vasu
, Nathan Denlinger
, et al.
Supplementary Figure 4 from Safety and Clinical Outcomes of a First-in-Human Trial of Point-of-Care Manufactured Trispecific CAR T Cells Targeting CD19, CD20, and CD22
2026
·
Sumithira Vasu
, Nathan Denlinger
, et al.
Supplementary Figure 6 from Safety and Clinical Outcomes of a First-in-Human Trial of Point-of-Care Manufactured Trispecific CAR T Cells Targeting CD19, CD20, and CD22
2026
·
Sumithira Vasu
, Nathan Denlinger
, et al.
Supplementary Figure 2 from Safety and Clinical Outcomes of a First-in-Human Trial of Point-of-Care Manufactured Trispecific CAR T Cells Targeting CD19, CD20, and CD22
2026
·
Sumithira Vasu
, Nathan Denlinger
, et al.
Supplementary Figure 3 from Safety and Clinical Outcomes of a First-in-Human Trial of Point-of-Care Manufactured Trispecific CAR T Cells Targeting CD19, CD20, and CD22
2026
·
Sumithira Vasu
, Nathan Denlinger
, et al.
Supplementary Table 2 from Safety and Clinical Outcomes of a First-in-Human Trial of Point-of-Care Manufactured Trispecific CAR T Cells Targeting CD19, CD20, and CD22
2026
·
Sumithira Vasu
, Nathan Denlinger
, et al.
Show more works
View as search
Works count:
12
Citation count:
1
H-index:
1
I10-index:
Year
Topic
Type